DVA

Business Profile & Competitive Position

DaVita Inc. operates in the Healthcare sector, specifically the Medical - Care Facilities industry, as one of the largest U.S. providers of kidney dialysis and related laboratory services. As of December 31, 2025, the company ran 2,657 outpatient dialysis centers in the United States serving roughly 200,500 patients, complemented by international operations spanning 585 centers across 14 countries and approximately 94,500 patients. Its service lines cover outpatient hemodialysis, hospital inpatient dialysis, home-based dialysis, and kidney-transplant support.

The reported margin structure is modest for a market-dominant service platform: net margin sits at 6.0%. That figure suggests pricing power is constrained by large-government and commercial reimbursement contracts rather than by local competition. Two quality distinctions stand out from its 10-K summary: DaVita has been an industry leader in CMS's Quality Incentive Program for 11 reported years and in CMS's Five-Star Quality Rating System for 10 reported years. Those are long streaks, which is consistent with a regulated, scale-based moat rather than a technology or brand moat.

The most striking financial signature, however, is ROE of -123.6%. With recent quarters showing positive net income, a negative ROE implies shareholders' equity is negative on a book basis. That makes ROE nearly useless as a profitability gauge here; it is a balance-sheet structure signal more than an operating-performance signal. For investors evaluating competitive position, the 6.0% net margin and the company's clinical quality track record are more informative than the headline ROE.

Financial Posture

DaVita carries an $11.8 billion market capitalization and trades at a P/E of 15.8 as of the latest data snapshot, when the stock was at $183.66 with an RSI of 45.8 and a 50-day EMA of $191.77. A P/E below the broader healthcare average, combined with a beta of 0.83, points to a stock that has historically moved less than the overall market and is priced without much growth premium.

The 6.0% net margin is the figure that defines earnings power: the company is profitable, but it is not extracting wide margins from its patient base. The negative book equity distorts traditional return metrics, so valuation work on DaVita tends to rely more on earnings-based multiples and free-cash-flow analysis than on ROE. A recent gurufocus.com headline on September 14, 2026, noted the stock had gained 4.3% and compared the price near $189.32 to a GF Value estimate of $195.67, giving readers a reference point for where fundamental models were pricing the equity at that time.

Strategic Priorities & Outlook

DaVita's most recent 10-K frames its strategy around reimagining kidney care to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. The company is building integrated care capabilities across the renal continuum, from chronic kidney disease through end-stage kidney disease and into kidney transplantation.

Operationally, this aligns with CMS's Comprehensive Kidney Care Contracting model, whose goals include delaying disease progression, steering appropriate patients toward home dialysis, and incentivizing transplants. Home dialysis and transplant support are lower-cost modalities than in-center hemodialysis, so the strategy also has a reimbursement efficiency angle. The financial backdrop to all of this is highly concentrated: U.S. dialysis represented roughly 86% of consolidated revenues, and the 10-K notes that nearly all non-hospital dialysis profits came from commercial payors. That concentration means the strategic push toward integrated care and alternative sites of service exists alongside a heavy dependence on the current U.S. commercial-payor reimbursement mix.

Macro & Geopolitical Exposure

As a Medical - Care Facilities operator, DaVita sits inside a heavily regulated, reimbursement-sensitive industry. The most relevant macro exposures include Medicare and Medicaid payment rates set by CMS, commercial insurance pricing trends, and any legislative or administrative change to the reimbursement mix for dialysis and kidney care. Because dialysis is life-sustaining for end-stage renal disease patients, demand is non-discretionary, but the price the system pays for that care is politically sensitive and frequently revisited.

Other sector-level exposures include medical labor costs, especially nursing and technician staffing; supply chain reliability for dialysis equipment and consumables; and pharmaceutical costs tied to anemia management and other dialysis-related medications. The international footprint adds currency and foreign-regulatory exposure, while domestic policy debates over home dialysis adoption and value-based kidney care models can shift the relative economics of in-center versus at-home treatment.

Recent Developments

Headline attention around DaVita has picked up in September 2026. On September 14, gurufocus.com highlighted a 4.3% gain and compared the then-price of $189.32 to a GF Value estimate of $195.67. On September 16, zacks.com published "DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors," and benzinga.com ran a story noting that Warren Buffett and Donald Trump have overlapping exposure to a basket of 17 stocks, including DaVita. On September 21, marketbeat.com included DaVita in a list of "3 Surging Stocks That Don't Need the AI Boom to Keep Winning."

These headlines share a common thread: DaVita is being discussed as a non-AI, healthcare-focused name that has drawn notice from high-profile investors and has outperformed recently. The Buffett/Trump overlap is a narrative datapoint, not an investment thesis; readers should treat it as evidence of institutional and celebrity-investor attention rather than a signal of future returns.

Earnings Behavior & Post-Earnings Drift

DaVita has beaten earnings estimates in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 2.3%. Over those quarters, the average 5-day price move after the report was 6.36%, classified as an "up" drift. At first glance that looks like a typical post-earnings momentum profile, but the underlying quarter-to-quarter moves are far more polarized than the averages suggest.

The last four reports illustrate the dispersion clearly. On August 4, 2026, DaVita reported EPS of $4.02 versus a $3.88 estimate, a 3.6% beat, yet the stock fell 17.24% the next day and 21.78% over the following five sessions. By contrast, the May 5, 2026, report delivered $2.87 against a $2.41 estimate, a 19.1% beat, and the stock surged 23.46% the next day and 27.7% over five days. The February 2, 2026, quarter showed a 4.9% beat ($3.40 vs. $3.24) and produced a 21.17% next-day jump and a 23.79% five-day gain. The October 29, 2025, quarter was a miss: actual EPS of $2.51 versus $3.17, a -20.8% surprise, sending the stock down 6.17% the next day and 4.27% over five days.

The takeaway is that the 75% beat rate and the modest 2.3% average surprise do not translate into a reliable "beat-then-drift" pattern. A single quarter can dominate the average and send the stock in the opposite direction of the surprise. For the upcoming October 28, 2026, report, with the unofficial consensus at EPS of $3.58, traders should weigh the headline number alongside guidance, commercial-payor commentary, and any Medicare reimbursement updates, because those factors—not just the beat or miss—have driven the post-earnings repricing.

For a deeper dive into how sell-side and institutional models are currently weighting these factors, readers should review the full institutional verdict rather than relying on headline earnings statistics alone.